0001520138-19-000027.txt : 20190212 0001520138-19-000027.hdr.sgml : 20190212 20190212163107 ACCESSION NUMBER: 0001520138-19-000027 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190212 DATE AS OF CHANGE: 20190212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55292 FILM NUMBER: 19591310 BUSINESS ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 312-283-5793 MAIL ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20181231_10q.htm FORM 10-Q FOR PERIOD ENDED DECEMBER 31, 2018
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

Form 10-Q

(Mark One) 

☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: December 31, 2018

 

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 000-55292

 

BIOVIE INC.

(Exact name of registrant as specified in its charter)

Nevada   46-2510769
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

11601 Wilshire Blvd Suite 1100
Los Angeles, CA 90025
(Address of principal executive offices, Zip Code)
 
(312)-283-5793
(Registrant's telephone number, including area code)
 
(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

   

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒                                          No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒                                          No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer  ☐ Accelerated filer  ☐

Non-accelerated filer

  ☐ Smaller reporting company  ☐
(Do not check if a smaller reporting company)   Emerging growth company  ☒

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐                                          No ☒

 

The number of shares outstanding of each of the issuer’s classes of common equity, as of December 31, 2018 was 315,053,673.

 
 
 
 

 TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements 1
  Condensed Balance Sheets as of December 31, 2018 (unaudited) and June 30, 2018 1
  Condensed Statements of Operations (unaudited) - for the three months and six months ended December 31, 2018 and 2017 2
 

Condensed Statements of Cash Flows (unaudited) - for the six months ended December 31, 2018 and 2017

3
  Condensed Statements of Changes in Stockholders’ Equity (unaudited) - for the period from July 1, 2017 through December 31, 2017 and from July 1, 2018 through December 31, 2018 4
  Notes to Unaudited Condensed Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
Item 3. Quantitative and Qualitative Disclosures About Market Risk 19
Item 4. Controls and Procedures 19

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings 20
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20
Item 3. Defaults Upon Senior Securities 20
Item 4. Mine Safety Disclosures   20
Item 5. Other Information   20
Item 6. Exhibits  
     
SIGNATURES 21

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

 

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie, Inc.

 

 
 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

 

Biovie Inc.

Condensed Balance Sheet

 

   December 31,  June 30,
   2018  2018*
ASSETS  (Unaudited)   
       
CURRENT ASSETS:      
Cash  $1,630,483   $45,800 
Total Current Assets   1,630,483    45,800 
           
OTHER  ASSETS:          
Intangible Assets, Net   1,669,292    1,783,980 
Goodwill   345,711    345,711 
Total Other Assets   2,015,003    2,129,691 
           
TOTAL ASSETS  $3,645,486   $2,175,491 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
CURRENT LIABILITIES:          
Accounts Payable and accrued expenses  $104,836   $884,207 
Accrued Payroll   —      354,167 
Total Current Liabilities   104,836    1,238,374 
           
LONG-TERM LIABILITIES:          
Demand Promissory Note   —      250,000 
Notes Payable, Related Parties   —      575,918 
 Total Long-Term Liabilities   —      825,918 
           
TOTAL LIABILITIES   104,836    2,064,292 
           
Commitments and contingencies (Note 7)   —      —   
           
STOCKHOLDERS' EQUITY          
           
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding   —      —   
Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at December 31, 2018 and June 30, 2018, respectively; 315,053,673 and 98,503,199 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively   31,505    9,850 
Additional paid in capital   9,267,311    4,870,475 
Accumulated deficit   (5,758,166)   (4,769,126)
Total Stockholders' Equity   3,540,650    111,199 
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $3,645,486   $2,175,491 

 

*Derived from audited balance sheet as of June 30, 2018

 

See accompanying notes to unaudited condensed financial statements

 -1-

Biovie Inc.

Condensed Statements of Operations

(Unaudited)

 

   Three Months  Three Months  Six Months  Six Months
   Ended  Ended  Ended  Ended
   December 31,  December 31,  December 31,  December 31,
   2018  2017  2018  2017
             
             
REVENUE  $—     $—     $—     $—   
                     
OPERATING EXPENSES:                    
Amortization   57,344    57,344    114,689    114,689 
Research and development expenses   206,019    186,841    400,540    228,695 
Selling, general and administrative expenses   237,507    250,622    477,069    813,655 
TOTAL OPERATING EXPENSES   500,870    494,807    992,297    1,157,039 
                     
LOSS FROM OPERATIONS   (500,870)   (494,807)   (992,298)   (1,157,039)
                     
OTHER EXPENSE (INCOME):                    
Other income   —      —      (51,400)   —   
Interest expense   —      7,875    271    8,485 
Interest income   (360)   —      (788)   (1)
TOTAL OTHER EXPENSE (INCOME), NET   (360)   7,875    (51,917)   8,544 
                     
                     
NET LOSS  $(500,510)   (502,682)  $(940,381)  $(1,165,523)
                     
Deemed dividend related to ratchet adjustment   —      —      48,659    —   
                     
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS  $(500,510)  $(502,682)  $(989,040)  $(1,165,523)
                     
NET LOSS PER SHARE BASIC AND DILUTED  $(0.00)  $(0.01)  $(0.00)  $(0.01)
                     
WEIGHTED AVERAGE NUMBER OF                    
COMMON  SHARES OUTSTANDING BASIC AND DILUTED   315,053,673    94,848,836    312,182,118    94,078,045 

 

See accompanying notes to unaudited condensed financial statements

 

 -2-

Biovie Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

   Six Months Ended  Six Months Ended
   December 31 2018  December 31 2017
       
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss  $(940,381)  $(1,165,523)
Adjustments to reconcile net loss to net cash to cash used in operating activities:          
Services paid with common stock   —      364,500 
Amortization of intangible assets   114,689    114,689 
Stock based compensation expense   19,697    39,773 
Gain on settlement of debt   51,400      
Changes in operating assets and liabilities          
(Decrease)/Increase in:          
Accounts payable   (456,422)   158,245 
Accrued payroll   —      125,000 
Net cash used in operating activities   (1,211,017)   (363,316)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayment of debt   (244,300)   (35,000)
Proceeds from issuance of preferred shares   3,040,000    —   
Proceeds from issuance of common stock and warrants   —      395,000 
Net cash provided by financing activities   2,795,700    360,000 
           
Net increase in cash   1,584,684    (3,316)
           
Cash, beginning of period   45,800    5,140 
           
Cash, end of period  $1,630,483   $1,824 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
  Cash paid for interest  $—     $—   
  Cash paid for taxes  $—     $—   
           
SCHEDULE OF NON-CASH FINANCING ACTIVITIES:          
   Conversion of preferred shares to common stock  $3,200,000   $—   
   Settlement of debt by issuance of common stock  $1,150,135   $—   
   Cashless exercise of warrants  $224   $—   
   Deemed dividends for ratchet adjustments to warrants  $48,659   $—   

 

See accompanying notes to unaudited condensed financial statements

 

 -3-

Biovie Inc.

Condensed Statements of Stockholders’ Equity

(Unaudited)

 

   Preferred  Preferred  Common  Common  Additional     Total
   Stock  Stock  Stock  Stock  Paid in  Accumulated  Stockholders'
   Shares  Amount  Shares  Amount  Capital  Deficit  Equity
                      
Balance, June 30, 2017   —     $—      91,925,000   $9,193   $3,483,134   $(2,335,009)  $1,157,318 
                                    
Issuance of shares in a private placement   —      —      1,169,091    117    244,883    —      245,000 
                                    
Issuance of shares for services   —      —      1,500,000    150    329,850    —      330,000 
                                    
Stock option compensation   —      —      —      —      12,752    —      12,752 
                                    
Net loss   —      —      —      —      —      (662,841)   (662,841)
                                    
Balance, September 30, 2017 (Unaudited)   —      —      94,594,091    9,460    4,070,619    (2,997,850)   1,082,229 
                                    
Issuance of shares in a private placement   —      —      227,273    23    49,977    —      50,000 
                                    
Issuance of shares for services   —      —      150,000    15    34,485    —      34,500 
                                    
Issuance of warrants in a private placement   —      —      —      —      100,000    —      100,000 
                                    
Stock option compensation   —      —      —      —      27,021    —      27,021 
                                    
Net loss   —      —      —      —      —      (502,682)   (502,682)
                                    
Balance, December 31, 2017 (Unaudited)   —     $—      94,971,364   $9,498   $4,282,102   $(3,500,532)  $791,068 
                                    
Balance, June 30, 2018   —     $—      98,503,199   $9,850   $4,870,475   $(4,769,126)  $111,199 
                                    
Issuance of preferred stock in a private placement   2,133,332    3,200,000    —      —      3,200,000    —      3,200,000 
                                    
Conversion of preferred stock to common stock   (2,133,332)   (3,200,000)   213,333,200    21,333    (21,333)   —      —   
                                    
Issuance of shares in exchange for debt settlement   —      —      975,361    98    1,150,037    —      1,150,135 
                                    
Stock option compensation   —      —      —      —      3,412    —      3,412 
                                    
Cashless exercise of warrants   —      —      2,241,913    224    (224)   —      —   
                                    
Deemed dividends for ratchet adjustment to warrants   —      —      —      —      48,659    (48,659)   —   
                                    
Net loss   —      —      —      —      —      (439,871)   (439,871)
                                    
Balance, September 30, 2018 (Unaudited)   —     $—      315,053,673   $31,505   $9,251,026   $(5,257,656)  $4,024,875 
                                    
Stock option compensation   —      —      —      —      16,285    —      16,285 
                                    
Net loss   —      —      —      —      —      (500,510)   (500,510)
                                    
Balance, December 31, 2018 (Unaudited)   —     $—      315,053,673   $31,505   $9,267,311   $(5,758,166)  $3,540,650 

 

See accompanying notes to unaudited condensed financial statements

 

 -4-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

1. Background Information

 

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In April 2017, the Company signed a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute Inc. in Richmond, VA, and began dosing patients with BIV201 in September 2017. As of January 2019, all six of the planned patients had been treated with BIV201 therapy or enrolled in this ongoing Phase 2a clinical trial.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. The Company has issued a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in Japan, and Europe, Hong Kong, and China.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

2. Liquidity and Going Concern

 

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception and has an accumulated deficit of approximately $5.8 million at December 31, 2018. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as continuing to secure additional financing.

 

 -5-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

2. Liquidity and Going Concern (continued)

 

In July 2018, the Company completed a capital raise from Acuitas Group Holding, LLC (“Acuitas”) and other purchasers and received net proceeds of $3.2 million and has resumed to further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may invest an additional $3 million to fund operations in year two, less any federal or FDA grant funding received by the Company.

 

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund continuing operations, if at all. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

  

3. Significant Accounting Policies

 

Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.

Net Loss per Common Share

Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

 -6-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

3. Significant Accounting Policies (continued)

 

The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:

 

   December 31, 2018  June 30, 2018
   Number of Shares  Number of Shares
Stock Options   5,550,000    5,150,000 
Warrants   216,440,548    4,774,015 
Total   221,990,548    9,924,015 

 

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.

 -7-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

4. Intellectual Property

 

Intellectual property, stated at cost, less accumulated amortization consists of the following:

   December 31, 2018  June 30, 2018
       
Intellectual Property  $2,293,770   $2,293,770 
Accumulated Amortization   624,478    509,790 
Intellectual Property, Net  $1,669,292   $1,783,980 

 

Amortization expense for the three- and six-month periods ended December 31, 2018 was $57,344 and $114,689, respectively, and for the three- and six-month periods ended December 30, 2017 was $57,344 and $114,689, respectively. Estimated future amortization expense is as follows:

 

Year ending June 2019 (remaining six months)  $                         114,689
2020                             229,377
2021                             229,377
2022                             229,377
2023                             229,377
Thereafter                             637,095
   $                      1,669,292

 

5. Renegotiated Debt

On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of Operations as “other income” for the six month period ended December 31, 2018.

 

 -8-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

6. Related Party Transactions

On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.

 

On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (“Barrett”) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital.

 

On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,203 and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.

 

7. Commitments and Contingencies 

Office Lease 

On October 1, 2018, the Company executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company’s office at 11601 Wilshire Blvd Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days’ written notice and requires monthly payments of $1,000.

Challenge to US Patent

On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie’s US Patent No. 9,655,945 titled “Treatment of Ascites” (the ‘945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

 -9-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

7. Commitments and Contingencies (continued) 

On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a rationale as to why, in the Company’s opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of the Company’s 14 claims was unpatentable. BioVie will seek to defend the ‘945 patent and/or pursue a favorable settlement. As of December 31, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc.

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

8. Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2018:

 

   Options  Weighted-Average Exercise Price  Weighted Remaining Average Contractual Term  Aggregate Intrinsic Value
Outstanding at June 30, 2018   5,150,000   $0.12    5.8   $—   
Granted   400,000   $0.06    4.6   $—   
Options Exercised   —     $—      —     $—   
Outstanding at December 31, 2018   5,550,000   $0.11    5.7   $—   
Exercisable at December 31, 2018   4,550,000   $0.11    5.7   $—   

 

 -10-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

8. Equity Transactions (continued)

The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions:

   December 31,
   2018  2017
Expected life of options (In years)   5    2 
Expected volatility   67.91%   69.66%
Risk ree interest rate   2.98%   1.59%
Dividend Yield   0%   0%

 

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stick and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $16,285 and $19,697 for the three-and six-month periods ended December 31, 2018, respectively, and $27,021 and $39,773 for the three-and six-month periods ended December 31, 2017, respectively.

The fair value of options vested during the six-month period ended December 31, 2018 and 2017, was $6,823 and $16,854 respectively.

As of December 31, 2018, there was approximately $4,966 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized over a weighted-average period of 4 months.

The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2018:

      Weighted Average    
Exercise Price  Outstanding  Contract Life  Exercisable
$0.05    300,000    4.8    300,000 
$0.06    3,100,000    7.2    2,100,000 
$0.07    100,000    4.8    100,000 
$0.10    500,000    4.1    500,000 
$0.20    200,000    3.8    200,000 
$0.21    550,000    3.3    550,000 
$0.22    100,000    3.2    100,000 
$0.23    200,000    3.6    200,000 
$0.25    500,000    2.9    500,000 
 Total    5,550,000         4,550,000 

 

 -11-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

8. Equity Transactions (continued)

Offerings of Common Stock and Warrants

Issuance of Shares for Cash

On July 3, 2018, BioVie, Inc., the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) the Company will issue associated warrants (the “Warrants”) to purchase 213,333,200 shares of the Company’s Class A Common Stock (the “Common Stock”), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.

 

Each share of Preferred Stock automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company’s Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company’s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company’s Definitive Information that was filed with the Securities and Exchange Commission.

 

The purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the Company’s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.

 

 -12-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

8. Equity Transactions (continued)

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company’s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company’s obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company.

 

Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company’s Board of Directors (the “Board”) and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.

 

Issuance of Shares in Settlement of Debt

During the six months ended December 31, 2018, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common stock with a fair value of $1,150,135. See notes 5 and 6.

Issuance of Stock Options

On October 1, 2018, the Company issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 13, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 27, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance

On November 10, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.

 -13-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

8. Equity Transactions (continued)

Cashless exercise of warrant

On August 4, 2018, the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.

 

Warrant Price Adjustment

In December 2017, the Company issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.

 

In January 2018, the Company issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value. The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.

The following table summarizes the warrants that have been issued:

   Number of  Weighted Average  Weighted Average Remaining 

Aggregate

Intrinsic

   Shares  Exercise Price  Life (Years)  Value
Outstanding at June 30, 2018   4,774,015   $0.29    5.0   $—   
Granted   214,166,533   $0.02    5.5   $2,141,665 
Expired   —     $—      —     $—   
Exercised   (2,500,000)  $0.02    —     $—   
Outstanding and exercisable at December 31, 2018   216,440,548   $0.02    5.5   $2,141,665 

 

Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year ending June 30, 2025.

 -14-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2018 and 2017

(unaudited)

 

9. Subsequent Event

On January 15, 2019, the Company issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $0.035 per share.

On January 19, 2019, the Company issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.

 -15-

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

 

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc.

 

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

 

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales, expenses and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

 

Management’s Discussion

 

Biovie is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies targeting life-threatening complications of liver cirrhosis. Our initial disease target is ascites, a serious medical condition affecting about 100,000 Americans and many times more worldwide. Our therapeutic drug candidate BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. The active agent in BIV201, terlipressin, is a potent vasoconstrictor which is in use for various medical conditions around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

 

 -16-

Comparison of the three months ended December 31, 2018 to the three months ended December 31, 2017

 

Total operating expenses for the three months ended December 31, 2018 were $501,000 compared to $495,000 for the three months ended December 31, 2017.  The net increase of $6,000 was primarily due to a $19,000 increase in research and development expenses due to the timing of clinical trials, offset by a $13,000 reduction in selling, general and administrative expenses due to the issuance of common stock in 2017 as compensation for professionals.

 

Research and Development Expenses

Research and development expenses were $206,000 for the three months ended December 31, 2018, an increase of $19,000, from $187,000 for the three months ended December 31, 2017. The increase was primarily attributed to the timing of when clinical trials were run.

 

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $238,000 for the three months ended December 31, 2018, a decline of $13,000, compared to $251,000 for the three months ended December 31, 2017. In 2017, the Company paid for professional fees with BioVie common stock.

 

Comparison of the six months ended December 31, 2018 to the six months ended December 31, 2017

 

Total operating expenses for the six months ended December 31, 2018 were $992,000 compared to $1,157,000 for the six months ended December 31, 2017.  The net decrease of $165,000 was primarily due to a $337,000 reduction in selling, general and administrative expenses due to the issuance of common stock in 2017 as compensation for professionals, offset by the increase in research and development expenses of $172,000 as the Company resumed its clinical trial program and hired two full time employees in November 2018.

 

Research and Development Expenses

Research and development expenses were $401,000 for the six months ended December 31, 2018, an increase of $172,000, from $229,000 for the six months ended December 31, 2018. The increase was primarily attributed to continued analytical research and associated regulatory and clinical trial program planning and the Phase 2a clinical trial activities which began in July 2018.

 

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $477,000 for the six months ended December 31, 2018, a decline of $337,000, from $814,000 for the six months ended December 31, 2017. In 2017, the Company paid for professional fees related to financial and strategic advisory services with BioVie common stock.

 

Capital Resources and Liquidity

 

The Company completed a capital raise of $3.2 million in July 2018 which enabled the Company to resume and further develop its products. At December 31, 2018 the Company had $1.6 million of cash to complete its Phase 2 clinical trials of the BIV201 therapy and initiate the next Phase 2b clinical trials. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured.

As of December 31, 2018, the Company had an accumulated deficit of $5.8 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

 

 -17-

In July 2018 it completed a capital raise from Acuitas Group Holding, LLC (“Acuitas”) and other purchasers and received gross proceeds of $3.2 million and has resumed to further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may invest an additional $3 million to fund operations in year two, less any federal or FDA grant funding received by the Company.

 

We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.

 

Management intends to attempt to secure additional required funding primarily through additional equity or debt financings.  We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions.  However, there can be no assurance that we will be able to obtain required funding.  If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols.  If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.

 

These circumstances raise substantial doubt on our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

  

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets. 

 

Critical Accounting Policies and Estimates

 

For the six-month period ended December 31, 2018, there were no significant changes to the Company’s critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2018.

New Accounting Pronouncements

 

The Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

 

 -18-

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable

 

Item 4.  Controls and Procedures

 

We maintain “disclosure controls and procedures, “ such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulate and communicated to our management, including our Chief Executive Office and Chief Financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and procedures. The design of and disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Based upon their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act), except as noted below, that occurred during the quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

The Company had reported material weaknesses in its’ Form 10-K for the fiscal year ended June 30, 2018 filed on October 5, 2018 with the Securities Exchange Commission. Those material weaknesses have been remediated as follows: In October the Company hired a Chief Financial Officer and remediated the lack of segregation of duties and formalized certain controls and procedures related thereto. In addition, the Company’s board of directors have appointed an audit committee chair and audit committee consisting of three independent board of director members.

 

The Company’s Independent Registered Public Accounting Firm did not, and was not, required to provide an auditor attestation of the Company’s internal controls over financial reporting as described in Section 404(b) of the Sarbanes-Oxley Act.

 

 -19-

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

To our knowledge, neither the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

 

Item 2. Unregistered sales of equity securities

 

None

 

Item 3. Defaults Upon Senior Securities

 

None

 

Item 4.  Mine Safety Disclosures

 

None

 

Item 5.  Other Information

 

None

 

Item 6. Exhibits

 

(a) Exhibit index

 

Exhibits 
 
31.1   Certification of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
     
31.2   Certification of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
   
32.1   Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certifications of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

               

 (b)  Reports on Form 8-K

 

None.

 

 -20-

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioVie Inc.,

         
Signature   Titles   Date
         
   
/s/        

Terren Peizer

   Chairman and Chief Executive Officer (Principal Executive Officer)   February 12, 2019
         
/s/        

Joanne Wendy Kim 

   Chief Financial Officer    February 12, 2019
     
         
         

 

 -21-

 EX-31.1 2 bivi-20181231_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

     

I, Terren Peizer, certify that:
     
1. I have reviewed this quarterly report on Form 10-Q of Biovie, Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: February 12, 2019 

                /s/Terren S. Peizer
               
Terren S. Peizer
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 bivi-20181231_10qex31z2.htm EXHIBIT 31.2

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

     

I, Joanne Wendy Kim, certify that:
     
1. I have reviewed this quarterly report on Form 10-Q of Biovie, Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 12, 2019 

                /s/ Joanne Wendy Kim
               


Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 4 bivi-20181231_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

 

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Biovie, Inc., (the “Company”) on Form 10-Q for the period ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Terren Peizer, Chief Executive Officer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: February 12, 2019 

                /s/Terren S. Peizer
               
Terren S. Peizer
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 5 bivi-20181231_10qex32z2.htm EXHIBIT 32.2

Exhibit 32.1

 

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Biovie, Inc., (the “Company”) on Form 10-Q for the period ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: February 12, 2019 

                /s/ Joanne Wendy Kim
               


Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.LAB 6 bivi-20181231_lab.xml XBRL LABEL FILE Derivative Instrument [Axis] Stock Option [Member] StockOptionOneMember StockOptionTwoMember StockOptionThreeMember StockOptionFourMember StockOptionFiveMember StockOptionSixMember StockOptionSevenMember StockOptionEightMember StockOptionNineMember Equity Components [Axis] Preferred Stock Common Stock Capital in Excess of Par Value Accumulated Deficit Warrant [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Total Current Assets OTHER ASSETS: Intangible Assets (Net of Amortization) Goodwill Total Fixed Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts Payable and accrued expenses Accrued Payroll Total Current Liabilities LONG TERM LIABILITIES: Demand Promissory Note Notes Payable, Related Parties Total Long Term Liabilities TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at December 31, 2018 and June 30, 2018, respectively; 315,053,673 and 98,503,199 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively Additional paid in capital Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common Stock Shares Issued Common stock, shares outstanding Income Statement [Abstract] REVENUE OPERATING EXPENSES Amortization Research and development expenses Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME) Other Income Interest Expense Interest income TOTAL OTHER EXPENSE (INCOME) NET LOSS Deemed dividend NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS NET LOSS PER COMMON SHARE, BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash to cash used by operating activities: Services paid with common stock Amortization of intangible assets Stock based compensation expense Gain on settlement of debt Changes in operating assets and liabilities: Accounts Payable Accrued Payroll Net cash used by operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of debt Proceeds from issuance of preferred shares Proceeds from issuance of common stock and warrants Net cash provided by financing activities Net decrease in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for taxes NON-CASH INVESTING AND FINANCING ACTIVITIES Conversion of preferred shares to common stock Settlement of debt by issuance of common stock Cashless exercise of warrants Deemed dividends for ratchet adjustments to warrants Statement [Table] Statement [Line Items] Beginning Balance Beginning Balance, Shares Issuance of shares in a private placement Issuance of shares in a private placement (in shares) Issuance of shares for services Issuance of shares for services, Shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock (in shares) Issuance of shares in exchange for debt settlement Issuance of shares in exchange for debt settlement, Shares Issuance of warrants in a private placement Stock option compensation Cashless exercise of warrants, Shares Deemed dividends for ratchet adjustment to warrants Ending Balance Ending Balance, Shares Notes to Financial Statements Background Information Liquidity Accounting Policies [Abstract] Significant Accounting Policies Related Party Transactions [Abstract] Intellectual Property Renegotiated Debt Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Equity Transactions Subsequent Events [Abstract] Subsequent Events Basis of Presentation Net Loss per Common Share Recent accounting pronouncements Significant Accounting Policies Schedule of Dilutive securities were excluded from the computation of diluted loss per share Intellectual Property Schedule of Intangible Assets Schedule of Future expected Amortization of intangible assets Equity Transactions Schedule of Stock Option Issued Schedule of option outstanding and exercisable by exercise price Schedule of Warrants Issued Dilutive Securities excluded from the Computation of Diluted Loss Per Share Intellectual Property Intellectual Property Accumulated Amortization Intellectual Property, Net Intellectual Property 2019 2020 2021 2022 2023 Thereafter Option Outstanding at beginning of year Option Granted Option Exercised Option Forfeited Option Outstanding at end of year Option Excersiable at end of year Outstanding Weighted Average Exercise Price at the beginning Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Forfeited Outstanding Weighted Average Exercise Price at the end Excersiable Weighted Average Exercise Price at the end Weighted Average Remaining Contractual Term at the beginning Weighted Average Remaining Contractual Term, Granted Weighted Average Remaining Contractual Term, Excerised Weighted Average Remaining Contractual Term at the end Excersiable Weighted Average Remaining Contractual Term at the end Exercise Price Option Outstanding Weighted Average Contractual Life Option Excersiable Warrant Outstanding at the beginning of the year Warrant Granted Warrant Expired Warrant Exercised Warrant Outstanding at the end of year Weighted Average Exercise Price at the beginning of the year Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Exercised Weighted Average Exercise Price at the end of year Weighted Average Remaining Life at the beginning of the year Weighted Average Remaining Life, Granted Weighted Average Remaining Life at the end of year Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Granted Aggregate Intrinsic Value, Ending Balance Cashless Exercise of Warrants. Cashless Exercise of Warrants Shares Conversion Of Preferred Shares To Common Stock. Conversion Of Preferred Stock To Common Stock. Conversion Of Preferred Stock To Common Stock (in shares) Deemed Dividend Deemed Dividends for Ratchet Adjustments to Warrants. Deemed Dividends for Ratchet Adjustment to Warrant Demand Note [Text Block] Issuance Of Preferred Stock In Private Placement Issuance Of Preferred Stock In Private Placement (in shares) Issuance of Warrants in Private Placement Liquidity [Text Block] Settlement Of Debt By Issuance Of Common Stock Settlement of Debt by Issuance of Common Stock, Shares Per share weighted average intrinsic value of equity-based compensation awards excersied. Excludes stock and unit options. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Excerised, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Total Other Expense Income. Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Interest and Dividend Income Interest Income, Other TotalOtherExpenseIncome Document And Entity Information [Default Label] Income (Loss) Attributable to Parent, before Tax Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding EX-101.PRE 7 bivi-20181231_pre.xml XBRL PRESENTATION FILE EX-101.SCH 8 bivi-20181231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intellectual Property link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Renegotiated Note link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Intellectual Property (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Intellectual Property (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intellectual Property (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Equity Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equity Transactions (Details 3) link:presentationLink link:calculationLink link:definitionLink EX-101.INS 9 bivi-20181231.xml XBRL INSTANCE FILE 0001580149 2018-12-31 0001580149 2018-06-30 0001580149 2018-07-01 2018-12-31 0001580149 2017-07-01 2017-12-31 0001580149 2017-06-30 0001580149 2017-12-31 0001580149 2018-10-01 2018-12-31 0001580149 2017-10-01 2017-12-31 0001580149 us-gaap:StockOptionMember 2018-12-31 0001580149 bivi:StockOptionOneMember 2018-12-31 0001580149 bivi:StockOptionTwoMember 2018-12-31 0001580149 bivi:StockOptionThreeMember 2018-12-31 0001580149 bivi:StockOptionFourMember 2018-12-31 0001580149 bivi:StockOptionFiveMember 2018-12-31 0001580149 bivi:StockOptionSixMember 2018-12-31 0001580149 bivi:StockOptionSevenMember 2018-12-31 0001580149 us-gaap:StockOptionMember 2018-06-30 0001580149 bivi:StockOptionEightMember 2018-12-31 0001580149 bivi:StockOptionNineMember 2018-12-31 0001580149 us-gaap:PreferredStockMember 2017-07-01 2017-09-30 0001580149 us-gaap:PreferredStockMember 2017-10-01 2017-12-31 0001580149 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001580149 us-gaap:CommonStockMember 2017-10-01 2017-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2017-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2017-12-31 0001580149 us-gaap:RetainedEarningsMember 2017-07-01 2017-09-30 0001580149 us-gaap:RetainedEarningsMember 2017-10-01 2017-12-31 0001580149 2017-07-01 2017-09-30 0001580149 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:PreferredStockMember 2018-10-01 2018-12-31 0001580149 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001580149 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2018-12-31 0001580149 us-gaap:PreferredStockMember 2018-06-30 0001580149 us-gaap:PreferredStockMember 2018-12-31 0001580149 us-gaap:CommonStockMember 2018-06-30 0001580149 us-gaap:PreferredStockMember 2017-06-30 0001580149 us-gaap:PreferredStockMember 2017-09-30 0001580149 us-gaap:PreferredStockMember 2017-12-31 0001580149 us-gaap:PreferredStockMember 2018-09-30 0001580149 us-gaap:CommonStockMember 2017-06-30 0001580149 us-gaap:CommonStockMember 2017-09-30 0001580149 us-gaap:CommonStockMember 2017-12-31 0001580149 us-gaap:CommonStockMember 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001580149 us-gaap:RetainedEarningsMember 2018-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2017-06-30 0001580149 us-gaap:RetainedEarningsMember 2017-09-30 0001580149 us-gaap:RetainedEarningsMember 2017-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-09-30 0001580149 2017-09-30 0001580149 2018-09-30 0001580149 us-gaap:StockOptionMember 2017-07-01 2018-06-30 0001580149 us-gaap:WarrantMember 2017-07-01 2018-06-30 0001580149 us-gaap:WarrantMember 2018-07-01 2018-12-31 0001580149 us-gaap:StockOptionMember 2018-07-01 2018-12-31 0001580149 2017-07-01 2018-06-30 0001580149 bivi:StockOptionOneMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionTwoMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionThreeMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionFourMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionFiveMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionSixMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionSevenMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionEightMember 2018-07-01 2018-12-31 0001580149 bivi:StockOptionNineMember 2018-07-01 2018-12-31 0001580149 us-gaap:WarrantMember 2018-06-30 0001580149 us-gaap:WarrantMember 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares 1630483 45800 3645486 2175491 104836 884207 104836 1238374 9267311 4870475 3540650 111199 3645486 2175491 10000000 10000000 0 0 800000000 300000000 315053673 98503199 -1211017 -363316 2795700 360000 31505 9850 0.001 0.001 0 0 315053673 98503199 -456422 158245 1584684 -3316 1630483 45800 5140 1824 0.0001 0.0001 354167 125000 -5758166 -4769126 1669292 1783980 345711 345711 2015003 2129691 114689 114689 57344 57344 400540 228695 206019 186841 477069 813655 237507 250622 992297 1157039 500870 494807 -992298 -1157039 -500870 -494807 271 8485 7875 788 1 360 0.00 -0.01 0.00 -0.01 312182118 94078045 315053673 94848836 5550000 300000 3100000 100000 500000 200000 550000 100000 5150000 200000 500000 0.11 0.12 395000 364500 34500 150 15 329850 34485 330000 315053673 BIOVIE INC. 0001580149 10-Q 2018-12-31 false --06-30 Yes Non-accelerated Filer Q2 2019 825918 51400 104836 2064292 575918 -940381 -1165523 -500510 -502682 -662841 -502682 -662841 -439871 -500510 -439871 -48659 315053673 98503199 91925000 94594091 94971364 315053673 3540650 111199 1157318 791068 31505 9850 9193 9460 9498 31505 9267311 -5758166 4870475 -4769126 3483134 4070619 4282102 9251026 -2335009 -2997850 -3500532 -5257656 1082229 4024875 48659 -48659 51400 221990548 5150000 4774015 216440548 5550000 9924015 1669292 1783980 624478 509790 2293770 2293770 4550000 300000 2100000 100000 500000 200000 550000 100000 200000 500000 P5Y9M18D P4Y9M18D P7Y2M12D P4Y9M18D P4Y1M5D P3Y9M18D P3Y3M18D P3Y2M12D P3Y7M6D P2Y10M24D P5Y8M12D P5Y8M12D 4774015 216440548 0.29 0.02 P5Y6M 214166533 0.02 P5Y6M P5Y 0.05 0.06 0.07 0.10 0.20 0.21 0.22 0.23 0.25 3040000 3200000 1150135 98 1150037 1150135 224 224 -224 48659 50000 117 23 244883 49977 245000 3200000 3200000 3200000 1169091 227273 2133332 -3200000 21333 -21333 -2133332 213333200 19697 39773 16285 27021 12752 27021 12752 3412 16285 3412 0.11 -989040 -1165523 -500510 -502682 -51917 8484 -360 7875 250000 114689 229377 229377 229377 229377 637095 false true false -244300 -35000 1500000 150000 100000 100000 975361 2241913 <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: top"> <td style="width: 2%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></font></td> <td style="width: 98%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Background Information</b></font></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221;) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In April 2017, the Company signed a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute Inc. in Richmond, VA, and began dosing patients with BIV201 in September 2017.&#160;As of January 2019, all six of the planned patients had been treated with BIV201 therapy or enrolled in this ongoing Phase 2a clinical trial.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. The Company has issued a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in Japan, and Europe, Hong Kong, and China.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&#8220;PharmaIN&#8221;), LAT Pharma&#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company&#8217;s business plan.</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: top"> <td style="width: 2%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></font></td> <td style="width: 98%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity and Going Concern</b></font></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital. The Company&#8217;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception and has an accumulated deficit of approximately $5.8 million at December 31, 2018. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. The Company&#8217;s future operations are dependent on the success of the Company&#8217;s ongoing development and commercialization efforts, as well as continuing to secure additional financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2018, the Company completed a capital raise from Acuitas Group Holding, LLC (&#8220;Acuitas&#8221;) and other purchasers and received net proceeds of $3.2 million and has resumed to further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may invest an additional $3 million to fund operations in year two, less any federal or FDA grant funding received by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund continuing operations, if at all. These circumstances raise substantial doubt on the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: top"> <td style="width: 2%"><font style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></font></td> <td style="width: 98%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Significant Accounting Policies</b></font></td></tr> </table> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Basis of Presentation &#8211; Interim Financial Information</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a summary of significant accounting policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Net Loss per Common Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">December 31, 2018</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock Options</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,550,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,150,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">216,440,548</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,774,015</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">221,990,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,924,015</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Recent accounting pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standard Updates (&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&#8221;. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 2%"><b>4.</b></td><td style="width: 98%"><b>Intellectual Property</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intellectual property, stated at cost, less accumulated amortization consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">624,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">509,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,669,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,783,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense for the three- and six-month periods ended December 31, 2018 was $57,344 and $114,689, respectively, and for the three- and six-month periods ended December 30, 2017 was $57,344 and $114,689, respectively. Estimated future amortization expense is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 70%; text-align: center; padding-left: 5.4pt">Year ending June 2019 (remaining six months)</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">114,689</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; padding-left: 5.4pt">2020</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: center; padding-left: 5.4pt">2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; padding-left: 5.4pt">2022</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: center; padding-left: 5.4pt">2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">637,095</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-size: 11pt; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,669,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 2%"><b>5.</b></td><td style="text-align: justify; width: 98%"><b>Renegotiated Debt</b></td> </tr></table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of Operations as &#8220;other income&#8221; for the six month period ended December 31, 2018.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 2%"><b>6.</b></td><td style="text-align: justify; width: 98%"><b>Related Party Transactions</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&#8220;Barrett&#8221;) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,203 and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.</p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 2%"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>7.</b></font></td><td style="text-align: justify; width: 98%"><font style="font: 10pt/115% Times New Roman, Times, Serif"><b>Commitments and Contingencies</b></font></td> </tr></table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Office Lease&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2018, the Company executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&#8217;s office at 11601 Wilshire Blvd Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days&#8217; written notice and requires monthly payments of $1,000.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Challenge to US Patent</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie&#8217;s US Patent No. 9,655,945 titled &#8220;Treatment of Ascites&#8221; (the &#8216;945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a rationale as to why, in the Company&#8217;s opinion, Mallinckrodt&#8217;s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of the Company&#8217;s 14 claims was unpatentable. BioVie will seek to defend the &#8216;945 patent and/or pursue a favorable settlement. As of December 31, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Royalty Agreements</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and PharmaIN Corporation, LAT Pharma&#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 2%"><b>8.</b></td><td style="text-align: justify; width: 98%"><b>Equity Transactions</b></td> </tr></table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Stock Options</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the activity relating to the Company&#8217;s stock options for the six months ended December 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Remaining Average Contractual Term</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2018</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5.8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.06</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Options Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding at December 31, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5.7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Exercisable at December 31, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5.7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option &#8211; Pricing model reflecting the following weighted-average assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67.91</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">69.66</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Risk ree interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.98</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.59</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stick and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation expense of $16,285 and $19,697 for the three-and six-month periods ended December 31, 2018, respectively, and $27,021 and $39,773 for the three-and six-month periods ended December 31, 2017, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of options vested during the six-month period ended December 31, 2018 and 2017, was $6,823 and $16,854 respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2018, there was approximately $4,966 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized over a weighted-average period of 4 months.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td> <td colspan="3" style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-size: 11pt">&#160;</td> <td colspan="3" style="font-size: 11pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contract Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercisable</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 22%; text-align: right">$0.05</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 21%; text-align: right">4.8</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.06</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">7.2</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right">$0.07</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">4.8</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.10</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">4.1</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right">$0.20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.8</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.21</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.3</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right">$0.22</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.2</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.6</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right; padding-bottom: 1pt">$0.25</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right; padding-bottom: 1pt">2.9</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 2.5pt">&#160;</td> <td style="font-size: 11pt; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Offerings of Common Stock and Warrants</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Issuance of Shares for Cash</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 3, 2018, BioVie, Inc., the Company, entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &#8220;Purchasers&#8221;) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&#8217;s newly created Series A Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) at a price per share of $1.50 per share of Preferred Stock (the &#8220;Initial Sale&#8221;) and (ii) the Company will issue associated warrants (the &#8220;Warrants&#8221;) to purchase 213,333,200 shares of the Company&#8217;s Class A Common Stock (the &#8220;Common Stock&#8221;), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the &#8220;Subsequent Sale&#8221;) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of Preferred Stock automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company&#8217;s Articles of Incorporation (the &#8220;Amendment&#8221;) on August 13, 2018 that increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company&#8217;s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company&#8217;s Definitive Information that was filed with the Securities and Exchange Commission.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the Company&#8217;s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company&#8217;s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company&#8217;s obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Issuance of Shares in Settlement of Debt</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2018, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common stock with a fair value of $1,150,135. See notes 5 and 6.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Issuance of Stock Options </i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2018, the Company issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years from the date of issuance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 13, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 27, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 10, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cashless exercise of warrant</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 4, 2018, the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Warrant Price Adjustment</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2017, the Company issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2018, the Company issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value. The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the warrants that have been issued:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average Remaining</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></p> <p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></p></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life (Years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2018</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,774,015</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5.0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">214,166,533</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,141,665</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-left: 5.4pt">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,500,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2018</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">216,440,548</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5.5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,141,665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year ending June 30, 2025.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 2%"><b>9.</b></td><td style="text-align: justify; width: 98%"><b>Subsequent Event</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Company issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $0.035 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 19, 2019, the Company issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Basis of Presentation &#8211; Interim Financial Information</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a summary of significant accounting policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Net Loss per Common Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">December 31, 2018</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock Options</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,550,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,150,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">216,440,548</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,774,015</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">221,990,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,924,015</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Recent accounting pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standard Updates (&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&#8221;. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">December 31, 2018</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock Options</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,550,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 8%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 12%; border-bottom: Black 1pt solid; text-align: right">5,150,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">216,440,548</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,774,015</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">221,990,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,924,015</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intellectual property, stated at cost, less accumulated amortization consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">624,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">509,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,669,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,783,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated future amortization expense is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 70%; text-align: center; padding-left: 5.4pt">Year ending June 2019 (remaining six months)</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">114,689</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; padding-left: 5.4pt">2020</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: center; padding-left: 5.4pt">2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; padding-left: 5.4pt">2022</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: center; padding-left: 5.4pt">2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">637,095</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-size: 11pt; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,669,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the activity relating to the Company&#8217;s stock options for the six months ended December 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Remaining Average Contractual Term</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2018</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5.8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.06</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Options Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding at December 31, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5.7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Exercisable at December 31, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5.7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option &#8211; Pricing model reflecting the following weighted-average assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67.91</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">69.66</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Risk ree interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.98</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.59</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td> <td colspan="3" style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-size: 11pt">&#160;</td> <td colspan="3" style="font-size: 11pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contract Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercisable</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 22%; text-align: right">$0.05</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 21%; text-align: right">4.8</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.06</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">7.2</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right">$0.07</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">4.8</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.10</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">4.1</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right">$0.20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.8</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.21</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.3</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right">$0.22</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.2</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">$0.23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">3.6</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: right; padding-bottom: 1pt">$0.25</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right; padding-bottom: 1pt">2.9</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 2.5pt">&#160;</td> <td style="font-size: 11pt; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,550,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the warrants that have been issued:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average Remaining</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></p> <p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></p></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life (Years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2018</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,774,015</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5.0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">214,166,533</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,141,665</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-left: 5.4pt">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,500,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2018</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">216,440,548</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5.5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,141,665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> </table> 400000 0.06 P4Y7M6D -2500000 0.02 2141665 2141665 EX-101.CAL 10 bivi-20181231_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 bivi-20181231_def.xml XBRL DEFINITION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information
 6 Months Ended
Dec. 31, 2018
shares
Document And Entity Information  
Entity Registrant Name BIOVIE INC.
Entity Central Index Key 0001580149
Document Type 10-Q
Document Period End Date Dec. 31, 2018
Amendment Flag false
Current Fiscal Year End Date --06-30
Is Entity's Reporting Status Current? Yes
Entity Filer Category Non-accelerated Filer
Entity Common Stock, Shares Outstanding 315,053,673
Document Fiscal Period Focus Q2
Document Fiscal Year Focus 2019
Entity Emerging Growth Company true
Entity Small Business false
Entity Ex Transition Period false
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheet (Unaudited) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
CURRENT ASSETS:    
Cash $ 1,630,483 $ 45,800
Total Current Assets 1,630,483 45,800
OTHER ASSETS:    
Intangible Assets (Net of Amortization) 1,669,292 1,783,980
Goodwill 345,711 345,711
Total Fixed Assets 2,015,003 2,129,691
TOTAL ASSETS 3,645,486 2,175,491
CURRENT LIABILITIES:    
Accounts Payable and accrued expenses 104,836 884,207
Accrued Payroll 354,167
Total Current Liabilities 104,836 1,238,374
LONG TERM LIABILITIES:    
Demand Promissory Note 250,000
Notes Payable, Related Parties 575,918
Total Long Term Liabilities 825,918
TOTAL LIABILITIES 104,836 2,064,292
Commitments and contingencies
STOCKHOLDERS' EQUITY    
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at December 31, 2018 and June 30, 2018, respectively; 315,053,673 and 98,503,199 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively 31,505 9,850
Additional paid in capital 9,267,311 4,870,475
Accumulated deficit (5,758,166) (4,769,126)
Total Stockholders' Equity 3,540,650 111,199
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 3,645,486 $ 2,175,491
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares
Dec. 31, 2018
Jun. 30, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 800,000,000 300,000,000
Common Stock Shares Issued 315,053,673 98,503,199
Common stock, shares outstanding 315,053,673 98,503,199
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]        
REVENUE
OPERATING EXPENSES        
Amortization 57,344 57,344 114,689 114,689
Research and development expenses 206,019 186,841 400,540 228,695
Selling, general and administrative expenses 237,507 250,622 477,069 813,655
TOTAL OPERATING EXPENSES 500,870 494,807 992,297 1,157,039
LOSS FROM OPERATIONS (500,870) (494,807) (992,298) (1,157,039)
OTHER EXPENSE (INCOME)        
Other Income (51,400)
Interest Expense 7,875 271 8,485
Interest income (360) (788) (1)
TOTAL OTHER EXPENSE (INCOME) (360) 7,875 (51,917) 8,484
NET LOSS (500,510) (502,682) (940,381) (1,165,523)
Deemed dividend 48,659
NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS $ (500,510) $ (502,682) $ (989,040) $ (1,165,523)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED $ 0.00 $ (0.01) $ 0.00 $ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED 315,053,673 94,848,836 312,182,118 94,078,045
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (940,381) $ (1,165,523)
Adjustments to reconcile net loss to net cash to cash used by operating activities:    
Services paid with common stock 364,500
Amortization of intangible assets 114,689 114,689
Stock based compensation expense 19,697 39,773
Gain on settlement of debt 51,400  
Changes in operating assets and liabilities:    
Accounts Payable (456,422) 158,245
Accrued Payroll 125,000
Net cash used by operating activities (1,211,017) (363,316)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt (244,300) (35,000)
Proceeds from issuance of preferred shares 3,040,000
Proceeds from issuance of common stock and warrants 395,000
Net cash provided by financing activities 2,795,700 360,000
Net decrease in cash 1,584,684 (3,316)
Cash, beginning of period 45,800 5,140
Cash, end of period 1,630,483 1,824
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest
Cash paid for taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES    
Conversion of preferred shares to common stock 3,200,000
Settlement of debt by issuance of common stock 1,150,135
Cashless exercise of warrants 224
Deemed dividends for ratchet adjustments to warrants $ 48,659
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Capital in Excess of Par Value
Accumulated Deficit
Total
Beginning Balance at Jun. 30, 2017 $ 9,193 $ 3,483,134 $ (2,335,009) $ 1,157,318
Beginning Balance, Shares at Jun. 30, 2017 91,925,000      
Issuance of shares in a private placement $ 117 244,883 245,000
Issuance of shares in a private placement (in shares) 1,169,091      
Issuance of shares for services $ 150 329,850 330,000
Issuance of shares for services, Shares 1,500,000      
Stock option compensation 12,752 12,752
Net loss (662,841) (662,841)
Ending Balance at Sep. 30, 2017 $ 9,460 4,070,619 (2,997,850) 1,082,229
Ending Balance, Shares at Sep. 30, 2017 94,594,091      
Beginning Balance at Jun. 30, 2017 $ 9,193 3,483,134 (2,335,009) 1,157,318
Beginning Balance, Shares at Jun. 30, 2017 91,925,000      
Issuance of shares for services         364,500
Issuance of shares in exchange for debt settlement        
Stock option compensation         39,773
Cashless exercise of warrants        
Net loss         (1,165,523)
Ending Balance at Dec. 31, 2017 $ 9,498 4,282,102 (3,500,532) 791,068
Ending Balance, Shares at Dec. 31, 2017 94,971,364      
Beginning Balance at Sep. 30, 2017 $ 9,460 4,070,619 (2,997,850) 1,082,229
Beginning Balance, Shares at Sep. 30, 2017 94,594,091      
Issuance of shares in a private placement $ 23 49,977 50,000
Issuance of shares in a private placement (in shares) 227,273      
Issuance of shares for services $ 15 34,485 34,500
Issuance of shares for services, Shares 150,000      
Issuance of warrants in a private placement 100,000 100,000
Stock option compensation 27,021 27,021
Net loss (502,682) (502,682)
Ending Balance at Dec. 31, 2017 $ 9,498 4,282,102 (3,500,532) 791,068
Ending Balance, Shares at Dec. 31, 2017 94,971,364      
Beginning Balance at Jun. 30, 2018 $ 9,850 4,870,475 (4,769,126) 111,199
Beginning Balance, Shares at Jun. 30, 2018 98,503,199      
Issuance of shares in a private placement $ 3,200,000 3,200,000 3,200,000
Issuance of shares in a private placement (in shares) 2,133,332      
Conversion of preferred stock to common stock $ (3,200,000) $ 21,333 (21,333)
Conversion of preferred stock to common stock (in shares) (2,133,332) 213,333,200      
Issuance of shares in exchange for debt settlement $ 98 1,150,037 1,150,135
Issuance of shares in exchange for debt settlement, Shares 975,361      
Stock option compensation 3,412 3,412
Cashless exercise of warrants $ 224 (224)
Cashless exercise of warrants, Shares 2,241,913      
Deemed dividends for ratchet adjustment to warrants 48,659 (48,659)
Net loss (439,871) (439,871)
Ending Balance at Sep. 30, 2018 $ 31,505 9,251,026 (5,257,656) 4,024,875
Ending Balance, Shares at Sep. 30, 2018 315,053,673      
Beginning Balance at Jun. 30, 2018 $ 9,850 4,870,475 (4,769,126) 111,199
Beginning Balance, Shares at Jun. 30, 2018 98,503,199      
Issuance of shares for services        
Issuance of shares in exchange for debt settlement         1,150,135
Stock option compensation         19,697
Cashless exercise of warrants         224
Net loss         (940,381)
Ending Balance at Dec. 31, 2018 $ 31,505 9,267,311 (5,758,166) 3,540,650
Ending Balance, Shares at Dec. 31, 2018 315,053,673      
Beginning Balance at Sep. 30, 2018 $ 31,505 9,251,026 (5,257,656) 4,024,875
Beginning Balance, Shares at Sep. 30, 2018 315,053,673      
Stock option compensation 16,285 16,285
Net loss (500,510) (500,510)
Ending Balance at Dec. 31, 2018 $ 31,505 $ 9,267,311 $ (5,758,166) $ 3,540,650
Ending Balance, Shares at Dec. 31, 2018 315,053,673      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Background Information
 6 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Background Information
1. Background Information

 

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In April 2017, the Company signed a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute Inc. in Richmond, VA, and began dosing patients with BIV201 in September 2017. As of January 2019, all six of the planned patients had been treated with BIV201 therapy or enrolled in this ongoing Phase 2a clinical trial.

 

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. The Company has issued a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its drug candidate in Japan, and Europe, Hong Kong, and China.

 

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

 

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity
 6 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Liquidity
2. Liquidity and Going Concern

 

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception and has an accumulated deficit of approximately $5.8 million at December 31, 2018. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as continuing to secure additional financing.

 

In July 2018, the Company completed a capital raise from Acuitas Group Holding, LLC (“Acuitas”) and other purchasers and received net proceeds of $3.2 million and has resumed to further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may invest an additional $3 million to fund operations in year two, less any federal or FDA grant funding received by the Company.

 

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund continuing operations, if at all. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies
 6 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Significant Accounting Policies
3. Significant Accounting Policies

 

Basis of Presentation – Interim Financial Information

 

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.

 

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.

 

Net Loss per Common Share

 

Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

 

The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:

 

   December 31, 2018  June 30, 2018
   Number of Shares  Number of Shares
Stock Options   5,550,000    5,150,000 
Warrants   216,440,548    4,774,015 
Total   221,990,548    9,924,015 

 

Recent accounting pronouncements

 

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

 

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intellectual Property
 6 Months Ended
Dec. 31, 2018
Related Party Transactions [Abstract]  
Intellectual Property
4.Intellectual Property

 

Intellectual property, stated at cost, less accumulated amortization consists of the following:

 

   December 31, 2018  June 30, 2018
       
Intellectual Property  $2,293,770   $2,293,770 
Accumulated Amortization   624,478    509,790 
Intellectual Property, Net  $1,669,292   $1,783,980 

 

Amortization expense for the three- and six-month periods ended December 31, 2018 was $57,344 and $114,689, respectively, and for the three- and six-month periods ended December 30, 2017 was $57,344 and $114,689, respectively. Estimated future amortization expense is as follows:

 

Year ending June 2019 (remaining six months)  $114,689 
2020   229,377 
2021   229,377 
2022   229,377 
2023   229,377 
Thereafter   637,095 
   $1,669,292 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Renegotiated Note
 6 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Renegotiated Debt
5.Renegotiated Debt

 

On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of Operations as “other income” for the six month period ended December 31, 2018.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
 6 Months Ended
Dec. 31, 2018
Related Party Transactions [Abstract]  
Related Party Transactions
6.Related Party Transactions

 

On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.

 

On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (“Barrett”) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital.

 

On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,203 and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 6 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
7.Commitments and Contingencies

 

Office Lease 

 

On October 1, 2018, the Company executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company’s office at 11601 Wilshire Blvd Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days’ written notice and requires monthly payments of $1,000.

 

Challenge to US Patent

 

On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie’s US Patent No. 9,655,945 titled “Treatment of Ascites” (the ‘945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

 

On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a rationale as to why, in the Company’s opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of the Company’s 14 claims was unpatentable. BioVie will seek to defend the ‘945 patent and/or pursue a favorable settlement. As of December 31, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.

 

Royalty Agreements

 

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc.

 

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

 

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Transactions
 6 Months Ended
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Equity Transactions
8.Equity Transactions

 

Stock Options

 

The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2018:

 

   Options  Weighted-Average Exercise Price  Weighted Remaining Average Contractual Term  Aggregate Intrinsic Value
Outstanding at June 30, 2018   5,150,000   $0.12    5.8   $—   
Granted   400,000   $0.06    4.6   $—   
Options Exercised   —     $—      —     $—   
Outstanding at December 31, 2018   5,550,000   $0.11    5.7   $—   
Exercisable at December 31, 2018   4,550,000   $0.11    5.7   $—   

 

The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions:

 

   December 31,
   2018  2017
Expected life of options (In years)   5    2 
Expected volatility   67.91%   69.66%
Risk ree interest rate   2.98%   1.59%
Dividend Yield   0%   0%

 

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stick and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

 

The Company recorded stock-based compensation expense of $16,285 and $19,697 for the three-and six-month periods ended December 31, 2018, respectively, and $27,021 and $39,773 for the three-and six-month periods ended December 31, 2017, respectively.

 

The fair value of options vested during the six-month period ended December 31, 2018 and 2017, was $6,823 and $16,854 respectively.

 

As of December 31, 2018, there was approximately $4,966 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized over a weighted-average period of 4 months.

 

The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2018:

 

      Weighted Average   
Exercise Price  Outstanding  Contract Life  Exercisable
$0.05   300,000   4.8   300,000 
$0.06   3,100,000   7.2   2,100,000 
$0.07   100,000   4.8   100,000 
$0.10   500,000   4.1   500,000 
$0.20   200,000   3.8   200,000 
$0.21   550,000   3.3   550,000 
$0.22   100,000   3.2   100,000 
$0.23   200,000   3.6   200,000 
$0.25   500,000   2.9   500,000 
Total   5,550,000       4,550,000 

 

Offerings of Common Stock and Warrants

 

Issuance of Shares for Cash

 

On July 3, 2018, BioVie, Inc., the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) the Company will issue associated warrants (the “Warrants”) to purchase 213,333,200 shares of the Company’s Class A Common Stock (the “Common Stock”), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.

 

Each share of Preferred Stock automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company’s Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company’s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company’s Definitive Information that was filed with the Securities and Exchange Commission.

 

The purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the Company’s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.

 

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company’s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company’s obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company.

 

Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company’s Board of Directors (the “Board”) and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.

 

Issuance of Shares in Settlement of Debt

 

During the six months ended December 31, 2018, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common stock with a fair value of $1,150,135. See notes 5 and 6.

 

Issuance of Stock Options

 

On October 1, 2018, the Company issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years from the date of issuance.

 

On October 13, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.

 

On October 27, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance

 

On November 10, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of issuance. 

 

Cashless exercise of warrant

 

On August 4, 2018, the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.

 

Warrant Price Adjustment

 

In December 2017, the Company issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.

 

In January 2018, the Company issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value. The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.

 

The following table summarizes the warrants that have been issued:

 

   Number of  Weighted Average  Weighted Average Remaining 

Aggregate

Intrinsic

   Shares  Exercise Price  Life (Years)  Value
Outstanding at June 30, 2018   4,774,015   $0.29    5.0   $—   
Granted   214,166,533   $0.02    5.5   $2,141,665 
Expired   —     $—      —     $—   
Exercised   (2,500,000)  $0.02    —     $—   
Outstanding and exercisable at December 31, 2018   216,440,548   $0.02    5.5   $2,141,665 

 

Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year ending June 30, 2025.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 6 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events
9.Subsequent Event

 

On January 15, 2019, the Company issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $0.035 per share.

 

On January 19, 2019, the Company issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
 6 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation – Interim Financial Information

 

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.

 

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.
Net Loss per Common Share

Net Loss per Common Share

 

Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

 

The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:

 

   December 31, 2018  June 30, 2018
   Number of Shares  Number of Shares
Stock Options   5,550,000    5,150,000 
Warrants   216,440,548    4,774,015 
Total   221,990,548    9,924,015 
Recent accounting pronouncements

Recent accounting pronouncements

 

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

 

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Tables)
 6 Months Ended
Dec. 31, 2018
Disclosure Significant Accounting Policies Tables Abstract  
Schedule of Dilutive securities were excluded from the computation of diluted loss per share

The table below shows the number of outstanding stock options and warrants as of December 31, 2018 and June 30, 2018:

 

   December 31, 2018  June 30, 2018
   Number of Shares  Number of Shares
Stock Options   5,550,000    5,150,000 
Warrants   216,440,548    4,774,015 
Total   221,990,548    9,924,015 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intellectual Property (Tables)
 6 Months Ended
Dec. 31, 2018
Disclosure Intangible Assets Tables Abstract  
Schedule of Intangible Assets

Intellectual property, stated at cost, less accumulated amortization consists of the following:

 

   December 31, 2018  June 30, 2018
       
Intellectual Property  $2,293,770   $2,293,770 
Accumulated Amortization   624,478    509,790 
Intellectual Property, Net  $1,669,292   $1,783,980 
Schedule of Future expected Amortization of intangible assets

Estimated future amortization expense is as follows:

 

Year ending June 2019 (remaining six months)  $114,689 
2020   229,377 
2021   229,377 
2022   229,377 
2023   229,377 
Thereafter   637,095 
   $1,669,292 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Transactions (Tables)
 6 Months Ended
Dec. 31, 2018
Disclosure Stock Options Tables Abstract  
Schedule of Stock Option Issued

The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2018:

 

   Options  Weighted-Average Exercise Price  Weighted Remaining Average Contractual Term  Aggregate Intrinsic Value
Outstanding at June 30, 2018   5,150,000   $0.12    5.8   $—   
Granted   400,000   $0.06    4.6   $—   
Options Exercised   —     $—      —     $—   
Outstanding at December 31, 2018   5,550,000   $0.11    5.7   $—   
Exercisable at December 31, 2018   4,550,000   $0.11    5.7   $—   

 

The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions:

 

   December 31,
   2018  2017
Expected life of options (In years)   5    2 
Expected volatility   67.91%   69.66%
Risk ree interest rate   2.98%   1.59%
Dividend Yield   0%   0%
Schedule of option outstanding and exercisable by exercise price

The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2018:

 

      Weighted Average   
Exercise Price  Outstanding  Contract Life  Exercisable
$0.05   300,000   4.8   300,000 
$0.06   3,100,000   7.2   2,100,000 
$0.07   100,000   4.8   100,000 
$0.10   500,000   4.1   500,000 
$0.20   200,000   3.8   200,000 
$0.21   550,000   3.3   550,000 
$0.22   100,000   3.2   100,000 
$0.23   200,000   3.6   200,000 
$0.25   500,000   2.9   500,000 
Total   5,550,000       4,550,000 
Schedule of Warrants Issued

The following table summarizes the warrants that have been issued:

 

   Number of  Weighted Average  Weighted Average Remaining 

Aggregate

Intrinsic

   Shares  Exercise Price  Life (Years)  Value
Outstanding at June 30, 2018   4,774,015   $0.29    5.0   $—   
Granted   214,166,533   $0.02    5.5   $2,141,665 
Expired   —     $—      —     $—   
Exercised   (2,500,000)  $0.02    —     $—   
Outstanding and exercisable at December 31, 2018   216,440,548   $0.02    5.5   $2,141,665 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Details) - shares
 6 Months Ended 12 Months Ended
Dec. 31, 2018
Jun. 30, 2018
Dilutive Securities excluded from the Computation of Diluted Loss Per Share 221,990,548 9,924,015
Warrant [Member]    
Dilutive Securities excluded from the Computation of Diluted Loss Per Share 216,440,548 4,774,015
Stock Option [Member]    
Dilutive Securities excluded from the Computation of Diluted Loss Per Share 5,550,000 5,150,000
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intellectual Property (Details) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Disclosure Intangible Assets Details Abstract    
Intellectual Property $ 2,293,770 $ 2,293,770
Accumulated Amortization 624,478 509,790
Intellectual Property, Net $ 1,669,292 $ 1,783,980
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intellectual Property (Details 2) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Disclosure Intangible Assets Details 2Abstract    
2019 $ 114,689  
2020 229,377  
2021 229,377  
2022 229,377  
2023 229,377  
Thereafter 637,095  
Intellectual Property, Net $ 1,669,292 $ 1,783,980
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Transactions (Details)
 6 Months Ended
Dec. 31, 2018
$ / shares
shares
Stock Option [Member]  
Option Outstanding at beginning of year 5,150,000
Option Granted 400,000
Option Exercised
Option Outstanding at end of year 5,550,000
Option Excersiable at end of year 4,550,000
Outstanding Weighted Average Exercise Price at the beginning | $ / shares $ 0.12
Weighted Average Exercise Price, Granted | $ / shares 0.06
Weighted Average Exercise Price, Exercised | $ / shares
Outstanding Weighted Average Exercise Price at the end | $ / shares 0.11
Excersiable Weighted Average Exercise Price at the end | $ / shares $ 0.11
Weighted Average Remaining Contractual Term at the beginning 5 years 9 months 18 days
Weighted Average Remaining Contractual Term, Granted 4 years 7 months 6 days
Weighted Average Remaining Contractual Term at the end 5 years 8 months 12 days
Excersiable Weighted Average Remaining Contractual Term at the end 5 years 8 months 12 days
StockOptionOneMember  
Option Outstanding at end of year 300,000
Option Excersiable at end of year 300,000
Weighted Average Remaining Contractual Term at the beginning 4 years 9 months 18 days
StockOptionTwoMember  
Option Outstanding at end of year 3,100,000
Option Excersiable at end of year 2,100,000
Weighted Average Remaining Contractual Term at the beginning 7 years 2 months 12 days
StockOptionThreeMember  
Option Outstanding at end of year 100,000
Option Excersiable at end of year 100,000
Weighted Average Remaining Contractual Term at the beginning 4 years 9 months 18 days
StockOptionFourMember  
Option Outstanding at end of year 500,000
Option Excersiable at end of year 500,000
Weighted Average Remaining Contractual Term at the beginning 4 years 1 month 5 days
StockOptionFiveMember  
Option Outstanding at end of year 200,000
Option Excersiable at end of year 200,000
Weighted Average Remaining Contractual Term at the beginning 3 years 9 months 18 days
StockOptionSixMember  
Option Outstanding at end of year 550,000
Option Excersiable at end of year 550,000
Weighted Average Remaining Contractual Term at the beginning 3 years 3 months 18 days
StockOptionSevenMember  
Option Outstanding at end of year 100,000
Option Excersiable at end of year 100,000
Weighted Average Remaining Contractual Term at the beginning 3 years 2 months 12 days
StockOptionEightMember  
Option Outstanding at end of year 200,000
Option Excersiable at end of year 200,000
Weighted Average Remaining Contractual Term at the beginning 3 years 7 months 6 days
StockOptionNineMember  
Option Outstanding at end of year 500,000
Option Excersiable at end of year 500,000
Weighted Average Remaining Contractual Term at the beginning 2 years 10 months 24 days
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Transactions (Details 2) - $ / shares
 6 Months Ended
Dec. 31, 2018
Jun. 30, 2018
StockOptionOneMember    
Exercise Price $ 0.05  
Option Outstanding 300,000  
Weighted Average Contractual Life 4 years 9 months 18 days  
Option Excersiable 300,000  
StockOptionTwoMember    
Exercise Price $ 0.06  
Option Outstanding 3,100,000  
Weighted Average Contractual Life 7 years 2 months 12 days  
Option Excersiable 2,100,000  
StockOptionThreeMember    
Exercise Price $ 0.07  
Option Outstanding 100,000  
Weighted Average Contractual Life 4 years 9 months 18 days  
Option Excersiable 100,000  
StockOptionFourMember    
Exercise Price $ 0.10  
Option Outstanding 500,000  
Weighted Average Contractual Life 4 years 1 month 5 days  
Option Excersiable 500,000  
StockOptionFiveMember    
Exercise Price $ 0.20  
Option Outstanding 200,000  
Weighted Average Contractual Life 3 years 9 months 18 days  
Option Excersiable 200,000  
StockOptionSixMember    
Exercise Price $ 0.21  
Option Outstanding 550,000  
Weighted Average Contractual Life 3 years 3 months 18 days  
Option Excersiable 550,000  
StockOptionSevenMember    
Exercise Price $ 0.22  
Option Outstanding 100,000  
Weighted Average Contractual Life 3 years 2 months 12 days  
Option Excersiable 100,000  
StockOptionEightMember    
Exercise Price $ 0.23  
Option Outstanding 200,000  
Weighted Average Contractual Life 3 years 7 months 6 days  
Option Excersiable 200,000  
StockOptionNineMember    
Exercise Price $ 0.25  
Option Outstanding 500,000  
Weighted Average Contractual Life 2 years 10 months 24 days  
Option Excersiable 500,000  
Stock Option [Member]    
Option Outstanding 5,550,000 5,150,000
Weighted Average Contractual Life 5 years 9 months 18 days  
Option Excersiable 4,550,000  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity Transactions (Details 3) - Warrant [Member]
 6 Months Ended
Dec. 31, 2018
USD ($)
$ / shares
shares
Warrant Outstanding at the beginning of the year | shares 4,774,015
Warrant Granted | shares 214,166,533
Warrant Expired | shares
Warrant Exercised | shares (2,500,000)
Warrant Outstanding at the end of year | shares 216,440,548
Weighted Average Exercise Price at the beginning of the year | $ / shares $ 0.29
Weighted Average Exercise Price, Granted | $ / shares 0.02
Weighted Average Exercise Price, Expired | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares 0.02
Weighted Average Exercise Price at the end of year | $ / shares $ 0.02
Weighted Average Remaining Life at the beginning of the year 5 years
Weighted Average Remaining Life, Granted 5 years 6 months
Weighted Average Remaining Life at the end of year 5 years 6 months
Aggregate Intrinsic Value, Beginning Balance | $
Aggregate Intrinsic Value, Granted | $ 2,141,665
Aggregate Intrinsic Value, Ending Balance | $ $ 2,141,665
EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 79 139 1 false 15 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nanoantibiotics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheet (Unaudited) Sheet http://nanoantibiotics.com/role/BalanceSheet Condensed Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) Sheet http://nanoantibiotics.com/role/BalanceSheetParenthetical Condensed Balance Sheet (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://nanoantibiotics.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity Sheet http://nanoantibiotics.com/role/Liquidity Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://nanoantibiotics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Intellectual Property Sheet http://nanoantibiotics.com/role/IntellectualProperty Intellectual Property Notes 10 false false R11.htm 00000011 - Disclosure - Renegotiated Note Sheet http://nanoantibiotics.com/role/RenegotiatedNote Renegotiated Note Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://nanoantibiotics.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://nanoantibiotics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Equity Transactions Sheet http://nanoantibiotics.com/role/EquityTransactions Equity Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://nanoantibiotics.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://nanoantibiotics.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://nanoantibiotics.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Intellectual Property (Tables) Sheet http://nanoantibiotics.com/role/IntellectualPropertyTables Intellectual Property (Tables) Tables http://nanoantibiotics.com/role/IntellectualProperty 18 false false R19.htm 00000019 - Disclosure - Equity Transactions (Tables) Sheet http://nanoantibiotics.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://nanoantibiotics.com/role/EquityTransactions 19 false false R20.htm 00000020 - Disclosure - Significant Accounting Policies (Details) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Intellectual Property (Details) Sheet http://nanoantibiotics.com/role/IntellectualPropertyDetails Intellectual Property (Details) Details http://nanoantibiotics.com/role/IntellectualPropertyTables 21 false false R22.htm 00000022 - Disclosure - Intellectual Property (Details 2) Sheet http://nanoantibiotics.com/role/IntellectualPropertyDetails2 Intellectual Property (Details 2) Details http://nanoantibiotics.com/role/IntellectualPropertyTables 22 false false R23.htm 00000023 - Disclosure - Equity Transactions (Details) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails Equity Transactions (Details) Details http://nanoantibiotics.com/role/EquityTransactionsTables 23 false false R24.htm 00000024 - Disclosure - Equity Transactions (Details 2) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails2 Equity Transactions (Details 2) Details http://nanoantibiotics.com/role/EquityTransactionsTables 24 false false R25.htm 00000025 - Disclosure - Equity Transactions (Details 3) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails3 Equity Transactions (Details 3) Details http://nanoantibiotics.com/role/EquityTransactionsTables 25 false false All Reports Book All Reports bivi-20181231.xml bivi-20181231.xsd bivi-20181231_cal.xml bivi-20181231_def.xml bivi-20181231_lab.xml bivi-20181231_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true ZIP 43 0001520138-19-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-19-000027-xbrl.zip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end